CATX

Perspective Therapeutics, Inc.

NYSEAdd to watchlist

Healthcare · Medical Devices

$2.88

+$0.00+0.00%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

5 open-market sales on file ($1.62M), none of them under a pre-arranged plan. Who, and when

Aug 24, 2026$2.88

−$0.31−9.72%over 1M

Session

Day range65% of range

$2.77$2.94

Fundamentals

Visualize fundamentals and more

Market cap: 347.47M
P/E ratio: -

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 52
dropped: 54
re-drafted: 92

Out of 210 passages in this year’s Item 1A.

New this year

The successful commercialization of any of our product candidates will require us to perform a variety of functions, including:

105 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Data privacy
Cybersecurity
Litigation
Product recalls
Export controls
Key people

And 12 more.

FDA approval
Investment in drug development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. We continue to incur …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Perspective Therapeutics, Inc. investor relations

What CATX has filed with the SEC. This is not Perspective Therapeutics, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Perspective Therapeutics, Inc.

Also filed under Medical Devices, ranked by how closely they sit beside CATX.

BSXBoston Scientific Corp.compare with CATX
MDTMedtronic plccompare with CATX
ABTAbbott Laboratories

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Data privacy
Cybersecurity
Litigation
Product recalls
Export controls
Key people

And 12 more.

FDA approval
Investment in drug development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. We continue to incur …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

EWEdwards Lifesciences Corpcompare with CATX

Ask about Perspective Therapeutics, Inc.

The assistant answers from what CATX has actually filed: 16 annual reports filed with the SEC, 9 Form 4 filings from the last year and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from CATX's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Perspective Therapeutics, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Perspective Therapeutics, Inc.

Be told the moment a CATX insider trades
Put Perspective Therapeutics, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Perspective Therapeutics, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Perspective Therapeutics, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

31 more events are on Measure

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 52
dropped: 54
re-drafted: 92

Out of 210 passages in this year’s Item 1A.

New this year

The successful commercialization of any of our product candidates will require us to perform a variety of functions, including:

105 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add